Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2019 · 10-Q
Revenue$674.00K$674.00K+10.3% vs Q1 2018 Net Income-$4.30M-$4.30MN/M vs Q1 2018 EPS Diluted$0.25$0.25+38.9% vs Q1 2018 Operating Income-$4,640,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,139,000— Margins · derivedOperating margin-688.4%−241.3 pt vs Q1 2018
Net margin-638.3%−224.0 pt vs Q1 2018
ended Nov 30, 2018 · filed Jan 14, 2019 · 45 d after period end